Read by QxMD icon Read


Leander Dony, Jonas Mackerodt, Scott Ward, Sarah Filippi, Michael P H Stumpf, Juliane Liepe
Motivation: Different experiments provide differing levels of information about a biological system. This makes it difficult, a priori, to select one of them beyond mere speculation and/or belief, especially when resources are limited. With the increasing diversity of experimental approaches and general advances in quantitative systems biology, methods that inform us about the information content that a given experiment carries about the question we want to answer, become crucial. Results: PEITH(Θ) is a general purpose, Python framework for experimental design in systems biology...
December 7, 2017: Bioinformatics
Frederikus A Klok, Walter Ageno, Stefano Barco, Harald Binder, Benjamin Brenner, Daniel Duerschmied, Klaus Empen, Pompilio Faggiano, Joachim H Ficker, Nazzareno Galiè, Alexandre Ghuysen, Matthias Held, Nadine Heydenreich, Menno V Huisman, David Jiménez, Matija Kozak, Irene M Lang, Mareike Lankeit, Thomas Münzel, Antoniu Petris, Piotr Pruszczyk, Kurt Quitzau, Sebastian Schellong, Kai-Helge Schmidt, Branislav S Stefanovic, Franck Verschuren, Anamaria Wolf-Puetz, Guy Meyer, Stavros V Konstantinides
No abstract text is available yet for this article.
December 2017: Thrombosis and Haemostasis
Nicoletta Riva, Livia Puljak, Lorenzo Moja, Walter Ageno, Holger Schünemann, Nicola Magrini, Alessandro Squizzato
OBJECTIVE: To explore disagreements in multiple systematic reviews (SRs) assessing the benefit-to-harm ratio of thrombolytic therapy in patients with intermediate-risk pulmonary embolism (PE). STUDY DESIGN AND SETTING: MEDLINE, EMBASE, CDSR and DARE were searched up to April 14, 2016. We included SRs and guidelines that evaluated thrombolytic therapy, compared to anticoagulation alone, in intermediate-risk PE. We calculated pooled risk ratio (RR) and absolute risk difference (RD), with interquartile range (IQR), for all-cause mortality, recurrent PE and major bleeding...
November 21, 2017: Journal of Clinical Epidemiology
Samuel Z Goldhaber
No abstract text is available yet for this article.
March 28, 2017: Journal of the American College of Cardiology
Stavros V Konstantinides, Eric Vicaut, Thierry Danays, Cecilia Becattini, Laurent Bertoletti, Jan Beyer-Westendorf, Helene Bouvaist, Francis Couturaud, Claudia Dellas, Daniel Duerschmied, Klaus Empen, Emile Ferrari, Nazzareno Galiè, David Jiménez, Maciej Kostrubiec, Matija Kozak, Christian Kupatt, Irene M Lang, Mareike Lankeit, Nicolas Meneveau, Massimiliano Palazzini, Piotr Pruszczyk, Matteo Rugolotto, Aldo Salvi, Olivier Sanchez, Sebastian Schellong, Bozena Sobkowicz, Guy Meyer
BACKGROUND: The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. OBJECTIVES: This study investigated the long-term prognosis of patients with intermediate-risk PE and the effect of thrombolytic treatment on the persistence of symptoms or the development of late complications. METHODS: The PEITHO (Pulmonary Embolism Thrombolysis) trial was a randomized (1:1) comparison of thrombolysis with tenecteplase versus placebo in normotensive patients with acute PE, right ventricular (RV) dysfunction on imaging, and a positive cardiac troponin test result...
March 28, 2017: Journal of the American College of Cardiology
Arnaldo Marín V, José Tomás Gazmuri B, Max Andresen V, Max Andresen
Therapy for submassive pulmonary embolism (intermediate risk), remains controversial. New evidence has appeared that may help us in the process of decision making. We review the relevant literature, outline prognostic factors, and discuss current recommendations and controversies regarding the available alternatives such as systemic and catheter-directed thrombolytic use.
July 2015: Revista Médica de Chile
Gerold Söffker, Stefan Kluge
Acute pulmonary embolism is an important differential diagnosis of acute chest pain. The clinical signs are often non-specific. However, diagnosis and therapy must be done quickly in order to reduce morbidity and mortality. The new (2014) European guidelines for acute pulmonary embolism (PE) focus on risk-adapted diagnostic algorithms and prognosis adapted therapy concepts. According to the hemodynamic presentation the division in a high-risk group (unstable patient with persistent hypotension or shock) or in non-high-risk groups (hemodynamically stable) was proposed...
January 2015: Deutsche Medizinische Wochenschrift
Gianfranco Alunni, Daniele Coen
No abstract text is available yet for this article.
November 2014: Giornale Italiano di Cardiologia
Jae Seung Lee
Venous thromboembolism (VTE), which includes pulmonary embolism and deep vein thrombosis, is an important cause of morbidity and mortality. The aim of this review is to summarize the findings from clinically important publications over the last year in the area of VTE. In this review, we discuss 11 randomized controlled trials published from March 2013 to April 2014. The COAG and the EU-PACT trials indicate that pharmacogenetic testing has either no usefulness in the initial dosing of vitamin K antagonists or marginal usefulness in the Caucasian population...
September 2014: Tuberculosis and Respiratory Diseases
Menno V Huisman, Anne J Fogteloo, Frederikus A Klok
International guidelines suggest that patients presenting with acute pulmonary embolism should be given routine thrombolysis on top of heparin. There is debate as to whether patients with acute pulmonary embolism who present in a haemodynamically stable condition, yet have signs of right ventricular dysfunction and increased troponin, actually need thrombolytic therapy. The results of the Pulmonary Embolism Thrombolysis study (PEITHO) show that in this particular patient group routine thrombolysis led to less haemodynamic decompensation or collapse, but that this advantage came with significantly higher incidences of haemorrhagic stroke and major extracranial bleeding...
2014: Nederlands Tijdschrift Voor Geneeskunde
Olivier Sanchez, Benjamin Planquette, Guy Meyer
PURPOSE OF REVIEW: Although early pulmonary revascularization is the treatment of choice for patients with high-risk (massive) pulmonary embolism, it remains controversial in patients with intermediate-risk (submassive) pulmonary embolism until recently. Recent published data on the management of high-risk and intermediate-risk pulmonary embolism patients will be the main focus of this review. RECENT FINDINGS: The PEITHO trial supports the rationale of risk stratification in normotensive patients with pulmonary embolism...
September 2014: Current Opinion in Pulmonary Medicine
Guy Meyer, Eric Vicaut, Thierry Danays, Giancarlo Agnelli, Cecilia Becattini, Jan Beyer-Westendorf, Erich Bluhmki, Helene Bouvaist, Benjamin Brenner, Francis Couturaud, Claudia Dellas, Klaus Empen, Ana Franca, Nazzareno Galiè, Annette Geibel, Samuel Z Goldhaber, David Jimenez, Matija Kozak, Christian Kupatt, Nils Kucher, Irene M Lang, Mareike Lankeit, Nicolas Meneveau, Gerard Pacouret, Massimiliano Palazzini, Antoniu Petris, Piotr Pruszczyk, Matteo Rugolotto, Aldo Salvi, Sebastian Schellong, Mustapha Sebbane, Bozena Sobkowicz, Branislav S Stefanovic, Holger Thiele, Adam Torbicki, Franck Verschuren, Stavros V Konstantinides
BACKGROUND: The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. METHODS: In a randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in normotensive patients with intermediate-risk pulmonary embolism. Eligible patients had right ventricular dysfunction on echocardiography or computed tomography, as well as myocardial injury as indicated by a positive test for cardiac troponin I or troponin T...
April 10, 2014: New England Journal of Medicine
S Konstantinides, M Lankeit
Management of acute pulmonary embolism (PE) has advanced considerably in the past year, and progress is expected to continue in 2013. To help determine the optimal management strategy for normotensive patients with intermediate-risk PE, the Pulmonary Embolism Thrombolysis (PEITHO) study completed enrolment of 1006 patients with evidence of right ventricular dysfunction (by echocardiography or computed tomography) plus a positive troponin test. Patients have been randomised to thrombolytic treatment with tenecteplase versus placebo, and the effects on clinical end points (death or haemodynamic collapse) assessed at 7 and 30 days...
2013: Hämostaseologie
(no author information available yet)
BACKGROUND: In acute pulmonary embolism (PE), overt right ventricular (RV) failure with cardiogenic shock indicates a poor prognosis. However, normotensive patients with acute RV dysfunction on echocardiography or computed tomography and with myocardial troponin elevation may also have an adverse outcome. Thrombolysis rapidly reverses RV pressure overload in PE, but it remains unclear whether it may improve the early and long-term clinical outcome of selected normotensive patients. DESIGN: The Pulmonary EmbolIsm THrOmbolysis (PEITHO) trial is a prospective, multicenter, international, randomized (1:1), double-blind comparison of thrombolysis with tenecteplase vs placebo in normotensive patients with confirmed PE, an abnormal right ventricle on echocardiography or computed tomography, and a positive troponin I or T test result...
January 2012: American Heart Journal
G Meyer
No abstract text is available yet for this article.
December 2008: Revue de Pneumologie Clinique
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"